- Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab 2018;20:5–21.
- Bastin M, Andreelli F. Dual GIP-GLP1-receptor agonists in the treatment of type 2 diabetes: a short review on emerging data and therapeutic potential. Diabetes Metab Syndr Obes 2019;12:1973–85.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 2018;18:3–14.
Findings
What does this study add?
- A dose-dependent superiority in lowering HbA1c was evident with all three tirzepatide doses versus all comparators.
- Mean HbA1c differences ranged from:
- −17.71 to –22.35 mmol/mol (−1.62% to –2.06%) versus placebo
- –3.22 to −10.06 mmol/mol (−0.29% to −0.92%) versus GLP-1RA
- −7.66 to −12.02 mmol/mol (−0.70% to −1.09%) versus basal insulin regimens.
- Tirzepatide was more efficacious in reducing body weight.
- Weight reductions versus GLP-1RA ranged from 1.68 kg to 7.16 kg with tirzepatide 5 mg and 15 mg.
- Compared to GLP-1RA, the odds ratio (OR) for achieving at least 5% weight loss with tirzepatide 5 mg, 10 mg, and 15 mg was 1.96, 4.79, and 4.57, respectively.
- All tirzepatide doses were more efficacious than GLP-1RA in achieving weight loss of at least 10% and 15%.
- The superiority of tirzepatide in terms of weight control was more pronounced in comparisons versus basal insulin.
- Incidence of hypoglycaemia with tirzepatide was similar to placebo and lower versus basal insulin.
- Nausea was more frequent with tirzepatide versus placebo, especially with tirzepatide 15 mg.
- Tirzepatide was also associated with higher incidence of vomiting and diarrhoea than placebo.
- Odds of gastrointestinal events were similar between tirzepatide and GLP-1RA, except for diarrhoea with tirzepatide 10 mg.
- Tirzepatide 15 mg led to higher discontinuations due to adverse events regardless of comparator.
- All tirzepatide doses were safe in terms of serious adverse events and mortality.
